Literature DB >> 31163374

MScanFit motor unit number estimation (MScan) and muscle velocity recovery cycle recordings in amyotrophic lateral sclerosis patients.

R S Kristensen1, H Bostock2, S V Tan3, A Witt1, A Fuglsang-Frederiksen1, E Qerama1, H Andersen4, H Tankisi5.   

Abstract

OBJECTIVE: Motor Unit Number Estimation (MUNE) methods, such as the recently developed MScanFit MUNE (MScan), may be valuable in tracking motor unit loss in ALS. Muscle Velocity Recovery Cycles (MVRCs) provide information about muscle membrane properties and can reveal disease-related changes. This study was undertaken to test the applicability of MScan to the anterior tibial muscle (TA) and to test whether the MVRCs could improve understanding of ALS pathophysiology.
METHODS: Twenty-six ALS patients and 25 healthy controls were evaluated by quantitative electromyography, nerve conduction study and the two novel methods: MScan and MVRC; all in the TA and peroneal nerve.
RESULTS: The estimated number of motor units for ALS patients (Median: 45, interquartile range: 28.5-76.5) was significantly lower than for the controls (117, 96.0-121.0) (P = 2.19 × 10-7). Unit size was increased only when amplitudes were expressed as percentage of CMAP. Of MVRC measurements, only relative refractory period was significantly abnormal in patients.
CONCLUSION: MScanFit MUNE gives a sensitive and quantitative measure of loss of TA motor units in ALS. Muscle fiber membrane properties are mostly unaffected, despite substantial denervation, presumably due to collateral reinnervation. SIGNIFICANCE: MScan is suitable for detecting motor unit loss in TA. MVRCs do not provide new insights in ALS.
Copyright © 2019 International Federation of Clinical Neurophysiology. All rights reserved.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; MScan; MVRC; Motor unit number estimation; Muscle velocity recovery cycles

Mesh:

Year:  2019        PMID: 31163374     DOI: 10.1016/j.clinph.2019.04.713

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  3 in total

1.  Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression.

Authors:  Steve Vucic; Matthew C Kiernan; Parvathi Menon; William Huynh; Austin Rynders; Karen S Ho; Robert Glanzman; Michael T Hotchkin
Journal:  BMJ Open       Date:  2021-01-11       Impact factor: 2.692

2.  The evolving role of surface electromyography in amyotrophic lateral sclerosis: A systematic review.

Authors:  J Bashford; K Mills; C Shaw
Journal:  Clin Neurophysiol       Date:  2019-12-27       Impact factor: 3.708

3.  Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen.

Authors:  Didu Kariyawasam; Arlene D'Silva; James Howells; Karen Herbert; Peter Geelan-Small; Cindy Shin-Yi Lin; Michelle Anne Farrar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-10-26       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.